Navigation Links
Cambrex Reports Third Quarter 2011 Results
Date:11/3/2011

gories, lower sales of generic APIs and lower custom development shipments.  

Gross margins in the third quarter of 2011 increased to 30.6% from 28.6% in the third quarter of 2010.  Excluding a favorable impact from foreign currency, third quarter of 2011 margins decreased to 27.3%.  The decline in currency adjusted gross margins was a result of lower pricing partially offset by higher production volumes and favorable product mix.  

Selling, General and Administrative Expenses in the third quarter of 2011 were $9.8 million compared to $7.9 million in the same period last year.  The increase is primarily due to increased personnel costs and foreign exchange.

Operating Profit increased to $5.4 million in the third quarter of 2011 from $1.3 million in the third quarter of 2010.  Operating Profit in the third quarter of 2011 increased $2.2 million compared to 2010 Adjusted Operating Profit of $3.2 million for the same period in 2010, driven primarily by favorable foreign exchange, higher sales volumes and favorable product mix partially offset by lower pricing and higher operating expenses.

Equity in Losses of Partially-Owned Affiliate of $0.5 million in the third quarter of 2011 represents the Company's share of losses in Zenara Pharma, a pharmaceutical company focused on the formulation of finished dosage form products.  Cambrex acquired a 51% stake in Zenara during the fourth quarter of 2010.  The Company's share of Zenara's losses includes $0.3 million of amortization of intangibles and depreciation.

Net Interest Expense decreased to $0.6 million in the third quarter of 2011 from $1.2 million in the third quarter of 2010.  This decrease is primarily due to the maturing of the Company's fixed interest rate swaps in October 2010.

The Provision for Income Taxes totaled $1.2 million in the third quarter of 2011.  The Company's effective tax rate has been and is expected to remai
'/>"/>

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cambrex to Announce Third Quarter 2011 Financial Results on November 3, 2011
2. Cambrex to Announce Second Quarter 2011 Financial Results on August 2, 2011
3. Cambrex Reports First Quarter of 2011 Results
4. Cambrex Reports Fourth Quarter and Full Year 2010 Results
5. Cambrex to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
6. Cambrex Zenara Manufacturing Facility Receives European GMP Approval
7. Shawn P. Cavanagh Appointed Chief Operating Officer of Cambrex
8. Cambrex Zenara Supplies Product for Launch of Nicorette® in India
9. Cambrex Acquires Stake in Zenara Pharma
10. Cambrex to Announce Third Quarter 2010 Financial Results on November 3, 2010
11. Cambrex Acquires IEP GmbH
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 The ... a Medical Fitness Center by the Medical Fitness Association, ... centers to achieve their full potential. The Cadence Fitness ... in the western suburbs and second in the Chicagoland ...
(Date:1/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ...
(Date:1/15/2014)... Jan. 15, 2014  A novel wearable injector slightly larger than ... for patients to self-inject prescription drugs in the large doses ... blood diseases, autoimmune deficiencies, and genetic disorders.  ... $220B by 2018, according to analysts.   Many of these drugs ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... Inc. (Nasdaq: OPTR ) announced today the ... 3 trials in patients with Clostridium difficile ... Infectious Disease Society of America (IDSA) in Vancouver, British ... M.D., of the University of Oxford, presented combined data ...
... PARK, Kan., Oct. 22 Mid*Lands IRB, LLC is ... by the Association for the Accreditation of Human Research ... Council on Accreditation.   Located in the ... board (IRB) that protects the rights and welfare of ...
Cached Medicine Technology:Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 2Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 3Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 4Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 5Mid*Lands IRB, LLC - First Independent IRB in Kansas and the Kansas City Area Awarded Accreditation for Protecting Research Participants 2
(Date:7/10/2014)... Alba,s research at the University of Huddersfield could help ... popular emulsion-based food products such as butter, mayonnaise, ... to gain an international profile for her work. , ... science at the University and now she has embarked ... supervisor, Dr Vassilis Kontogiorgos, she is investigating the potential ...
(Date:7/10/2014)... says the human brain operates much the same whether ... provide a better understanding of schizophrenia, bipolar disorder and ... 13.6 million Americans. , In newly published research in ... professor at the Center for Molecular and Behavioral Neuroscience, ... at rest is basically the same as that of ...
(Date:7/10/2014)... at sarcomas research group at the Bellvitge Biomedical Research ... have been tested in 19 patients a new therapeutic ... which indicate that the new treatment could stabilize the ... in the British Journal of Cancer ., ... and complex since there are several subtypes. It can ...
(Date:7/10/2014)... 10, 2014) Men who experience hot flashes are ... find relief from their silent suffering if they ... findings from a Baylor University case study., After seven ... had uncontrolled hot flashes following prostate cancer surgery showed ... also an impressive improvement in sleep quality, according to ...
(Date:7/9/2014)... of low back pain are not linked to weather ... and precipitation. Findings published in Arthritis Care & ... Rheumatology (ACR), indicate that the risk of low back ... gusts, but was not clinically significant. , According ... low back pain at some point in their life, ...
Breaking Medicine News(10 mins):Health News:World interest in research work on the benefits of the Okra plant 2Health News:Working to loosen the grip of severe mental illness 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Low back pain? Don't blame the weather 2
... die hard chocó fans could crack open a bar of ... its true colors and bares// its heart! When you melt ... a new finding. ,Researchers in the United ... an 18-month study to gauge the influence of aspirin on ...
... – whether from holiday feasts or rich desserts or alcoholic ... ,Heartburn – generally caused by naturally occurring acids ... by a characteristic burning sensation that sufferers describe as rolling ... in this process. ,“Most of the time heartburn ...
... The health crisis triggered by the death of over ... health institution's laboratory, has prompted Panamanian President// Martin Torrijos ... ,Torrijos said that the government had since ... Security Body (CSS), permanently in a bid to win ...
... A report released in the state of Pennsylvania, U.S,reveals that ... there in 2005.// ,The report the ... kind in various hospitals spread all over the state released ... have contracted hospital acquired infections when admitted there for some ...
... The genes of progeny are dependant on a fairly ... is potent enough to impact the genes of the ... consumed by expectant mice were seen to impact generation ... the National Academy of Sciences., ,To quote the ...
... Paris- Scientists from the Mecca of Fashion, Paris, have ... presence of a natural chemical called opiorphin//, a natural ... morphine., ,In their experiments, rodents were found to ... chemical in comparison with the usual dosage of morphine. ...
Cached Medicine News:Health News:Holiday Season Could Ring in “Heartburn Season 2Health News:Holiday Season Could Ring in “Heartburn Season 3Health News:Hospital infections gaining ground in Pennsylvania hospitals 2
... Intended for the quantitative determination ... Reaction: kinetic, lag phase of ... by linear phase of at ... nm. Linearity: 100 mg/dL (35.6 ...
For the quantitative determination of Urea Nitrogen in serum. Linearity: 80 mg/dl. Reaction measured at 340 nm....
Intended for the quantitative determination of total bilirubin in serum. Modified evelynmalloy method. Endpoint reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... Powerwave is the first microplate spectrophotometer designed ... 7 days per week. With rugged hardware, ... Powerwave breaks the barrier of traditional spectrophotometry ... One instrument can easily read up to ...
Medicine Products: